이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Agios Pharmaceuticals 관리

관리 기준 확인 4/4

Agios Pharmaceuticals' CEO는 Brian Goff, Aug2022 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 3.42M, 23.4% 로 구성됩니다. 23.4% 급여 및 76.6% 보너스(회사 주식 및 옵션 포함). 는 $ 2.86M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 2.86M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 8 년입니다.

주요 정보

Brian Goff

최고 경영자

US$3.4m

총 보상

CEO 급여 비율	23.4%
CEO 임기	1.9yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	8.1yrs

최근 관리 업데이트

Recent updates

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Sep 07

CEO 보상 분석

Brian Goff 의 보수는 Agios Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

보상 대 시장: Brian 의 총 보상 ($USD 3.42M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 6.80M ).

보상과 수익: Brian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Brian Goff (55 yo)

1.9yrs

테뉴어

US$3,416,453

보상

Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brian Goff	CEO & Director	1.9yrs	US$3.42m	0.12% $ 2.8m
Cecilia Jones	Chief Financial Officer	1.8yrs	US$1.21m	0.026% $ 623.6k
James Burns	Corporate Secretary & Chief Legal Officer	2.5yrs	US$1.93m	0.065% $ 1.6m
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	2.8yrs	US$2.87m	0.069% $ 1.6m
Tsveta Milanova	Chief Commercial Officer	1.5yrs	US$3.73m	0.023% $ 556.1k
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	데이터 없음
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
T. Washburn	VP, Controller & Principal Accounting Officer	2.9yrs	데이터 없음	0.0027% $ 63.9k
Clive Patience	Chief Technical Operations Officer	7.1yrs	데이터 없음	데이터 없음
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: AGIO 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brian Goff	CEO & Director	1.9yrs	US$3.42m	0.12% $ 2.8m
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	데이터 없음
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jacqualyn Fouse	Chair of the Board of Directors	6.6yrs	US$447.25k	0.25% $ 5.9m
Jeffrey Capello	Independent Director	1.1yrs	US$663.68k	0.0035% $ 83.0k
Charles Sawyers	Member of Scientific Advisory Board	15.4yrs	데이터 없음	데이터 없음
Kaye Foster-Cheek	Lead Independent Director	9.6yrs	US$440.95k	0.013% $ 317.3k
David Schenkein	Independent Director	14.9yrs	US$417.25k	0.84% $ 20.0m
Matthew Vander Heiden	Member of Scientific Advisory Board	15.7yrs	데이터 없음	데이터 없음
Cynthia Smith	Independent Director	1.9yrs	US$419.91k	0.010% $ 239.0k

8.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: AGIO 의 이사회는 경험(평균 재직 기간 8 년)으로 간주됩니다.

Agios Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

CEO & Director notifies of intention to sell stock

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Chair of the Board of Directors exercised options and sold US$232k worth of stock

CEO & Director exercised options and sold US$277k worth of stock

Recent updates

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CEO & Director exercised options and sold US$325k worth of stock

Agios Pharmaceuticals, Inc. Announces Board Changes

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Director exercised options and sold US$226k worth of stock

Director exercised options and sold US$262k worth of stock

Director exercised options and sold US$269k worth of stock

Director exercised options and sold US$326k worth of stock

Chair of the Board of Directors exercised options and sold US$105k worth of stock

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Director exercised options and sold US$406k worth of stock

Director notifies of intention to sell stock

Insider exercised options and sold US$79k worth of stock

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Price target decreased to US$36.20

Price target increased to US$39.20

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Consensus forecasts updated

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios adds more than 13% after Novo deal to acquire rival Forma

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Pharmaceuticals appoints new board chair, CEO

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Agios: Approved Product, Upcoming Catalysts